ECSP14030538A - Inhibidores de dgat1 de éter cíclico de cabeza de puente - Google Patents

Inhibidores de dgat1 de éter cíclico de cabeza de puente

Info

Publication number
ECSP14030538A
ECSP14030538A ECIEPI201430538A ECPI201430538A ECSP14030538A EC SP14030538 A ECSP14030538 A EC SP14030538A EC IEPI201430538 A ECIEPI201430538 A EC IEPI201430538A EC PI201430538 A ECPI201430538 A EC PI201430538A EC SP14030538 A ECSP14030538 A EC SP14030538A
Authority
EC
Ecuador
Prior art keywords
cyclic ether
bridge head
dgat1 inhibitors
head cyclic
dgat1
Prior art date
Application number
ECIEPI201430538A
Other languages
English (en)
Inventor
Zecri Frédéric
Chen Xin
Ye Jiong
Yik Ching Mao Justin
Duvadie Rohit
Zheng Xuchun
Zheng Rui
Patel Sejal
Gai Yu
Ding Yiping
Liu Qian
Larrow Jay
Zhou Yizong
Harrison Tyler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14030538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP14030538A publication Critical patent/ECSP14030538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La invención se ref iere a los compuestos de la fórmula ( I ) : ( I ) út i les para el t ratamiento de los t rastornos mediados por aci l - t ransferasa de aci l -CoA-diaci l -gl icerol 1 (DGAT1) , por ejemplo, los t rastornos metaból icos. La invención también propor ciona métodos para el t ratamiento de los t rastornos, y los compuestos y las composiciones etc. para su t ratamiento.
ECIEPI201430538A 2012-04-27 2014-11-27 Inhibidores de dgat1 de éter cíclico de cabeza de puente ECSP14030538A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639341P 2012-04-27 2012-04-27
US201361787695P 2013-03-15 2013-03-15
CN2013072735 2013-03-15

Publications (1)

Publication Number Publication Date
ECSP14030538A true ECSP14030538A (es) 2015-11-30

Family

ID=48577190

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201430538A ECSP14030538A (es) 2012-04-27 2014-11-27 Inhibidores de dgat1 de éter cíclico de cabeza de puente

Country Status (26)

Country Link
US (2) US8993619B2 (es)
EP (1) EP2852590B1 (es)
JP (1) JP6042529B2 (es)
KR (1) KR20150013194A (es)
CN (1) CN104395309B (es)
AP (1) AP3592A (es)
AR (1) AR090859A1 (es)
AU (1) AU2013254307B2 (es)
BR (1) BR112014026760A8 (es)
CA (1) CA2870336A1 (es)
CL (1) CL2014002822A1 (es)
CO (1) CO7111275A2 (es)
CR (1) CR20140494A (es)
EA (1) EA025050B1 (es)
EC (1) ECSP14030538A (es)
ES (1) ES2624291T3 (es)
IL (1) IL235313A0 (es)
MA (1) MA37439B1 (es)
MX (1) MX357768B (es)
PE (2) PE20160802A1 (es)
PH (1) PH12014502413A1 (es)
SG (1) SG11201406526WA (es)
TN (1) TN2014000425A1 (es)
TW (1) TW201348239A (es)
UY (1) UY34767A (es)
WO (1) WO2013160873A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406757SA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN104292189B (zh) * 2014-09-03 2016-05-04 哈尔滨工业大学 一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法
CN104292190B (zh) * 2014-09-03 2016-05-04 哈尔滨工业大学 一种β-溴代四氢呋喃类化合物的合成方法
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20210060546A (ko) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PE20050157A1 (es) 2003-05-20 2005-05-17 Novartis Ag Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
JP2008509146A (ja) * 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッド １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのスルホニル化合物
CA2647819C (en) * 2006-03-31 2012-12-11 Novartis Ag Phenylcyclohexyl derivatives as dgat1 inhibitors
NZ586104A (en) * 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
KR101900652B1 (ko) * 2010-10-07 2018-09-19 노파르티스 아게 （4-｛4-［5-（6-트리플루오로메틸-피리딘-3-일아미노）-피리딘-2-일］-페닐｝-시클로헥실）-아세트산의 나트륨 염의 신규 결정형
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators

Also Published As

Publication number Publication date
JP2015514798A (ja) 2015-05-21
TW201348239A (zh) 2013-12-01
PE20150724A1 (es) 2015-05-17
KR20150013194A (ko) 2015-02-04
WO2013160873A1 (en) 2013-10-31
PE20160802A1 (es) 2016-09-03
US8993619B2 (en) 2015-03-31
AR090859A1 (es) 2014-12-10
CO7111275A2 (es) 2014-11-10
BR112014026760A2 (pt) 2017-06-27
MA37439B1 (fr) 2017-02-28
UY34767A (es) 2013-11-29
US20130289058A1 (en) 2013-10-31
AU2013254307B2 (en) 2016-05-26
EP2852590B1 (en) 2017-02-01
EA201491970A1 (ru) 2015-03-31
CN104395309A (zh) 2015-03-04
CN104395309B (zh) 2016-09-28
TN2014000425A1 (en) 2016-03-30
MX2014013002A (es) 2015-01-22
PH12014502413A1 (en) 2015-01-12
CR20140494A (es) 2015-03-13
ES2624291T3 (es) 2017-07-13
AU2013254307A1 (en) 2014-10-30
EA025050B1 (ru) 2016-11-30
CA2870336A1 (en) 2013-10-31
EP2852590A1 (en) 2015-04-01
CL2014002822A1 (es) 2015-04-24
IL235313A0 (en) 2014-12-31
BR112014026760A8 (pt) 2018-01-16
AP2014008018A0 (en) 2014-10-31
JP6042529B2 (ja) 2016-12-14
MX357768B (es) 2018-07-24
MA37439A1 (fr) 2016-07-29
US20150166563A1 (en) 2015-06-18
AP3592A (en) 2016-02-15
SG11201406526WA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
ECSP14030538A (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
EA201792355A1 (ru) Способ получения противоракового средства 1-((4-(4-фтор-2-метил-1h-индол-5-илокси)-6-метоксихинолин-7-илокси)метил)циклопропанамина, его кристаллической формы и солей
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201591527A1 (ru) Новые производные пиридина
CR20140464A (es) Compuestos de heterociclilo
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
BR112015004111A2 (pt) novos derivados bicíclicos
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
EA201690844A1 (ru) Ингибиторы gsk-3
CR20140195A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
CR20140554A (es) Compuestos de acido dimetil-benzoico
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CR20140135A (es) Nuevos derivados de aril-quinolina
EA201490037A1 (ru) Антагонисты trpv4
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
UY34491A (es) La composición herbicida que contiene ácido de 4-amino-3-cloro-6- (4-cloro-2-flúor-3-metoxifenil) pyridina-2-carboxílico o los derivados de los mismos y fluroxipir o los derivados de los mismos
EA201790570A1 (ru) Модуляторы р2х7
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk